Table 3.

Association between atopy and incidence of respiratory symptoms stratified by the treatment group and gender

Respiratory symptom	Total population		Males		Females
	OR (95% CI) of atopy		OR (95% CI) of atopy		OR (95% CI) of atopy
	Placebo	Budesonide	Placebo	Budesonide	Placebo	Budesonide
Wheezing at any time	1.15 (0.71–1.87)	0.79 (0.45–1.43)	1.24 (0.74–2.08)	0.92 (0.48–1.75)	0.64 (0.15–2.78)	0.43 (0.10–1.85)
Cough day/night or a.m.	1.79 (1.03–3.08)*	0.83 (0.42–1.62)	1.69 (0.93–3.08)#	0.84 (0.38–1.84)	2.52 (0.64–9.86)	0.60 (0.17–2.08)
Phlegm day/night or a.m.	1.50 (0.84–2.69)	0.91 (0.54–1.53)	1.55 (0.82–2.93)	0.85 (0.46–1.59)	1.30 (0.36–4.67)	0.92 (0.38–2.27)
Trouble with breathing	1.12 (0.66–1.89)	0.68 (0.37–1.24)	1.09 (0.59–1.99)	0.79 (0.42–1.51)	1.23 (0.44–3.44)	0.22 (0.4–1.13)#
Woken with chest tightness	1.33 (0.74–2.38)	1.07 (0.57–1.99)	1.35 (0.69–2.65)	1.08 (0.55–2.12)	1.08 (0.27–4.34)	1.11 (0.23–5.39)
Attack of dyspnea after activity	0.98 (0.59–1.62)	1.49 (0.88–2.51)	0.76 (0.43–1.33)	1.55 (0.88–2.73)$	2.79 (0.94–8.31)#	0.89 (0.22–3.62)

*OR is significant at p < 0.05. Each model was adjusted for sex, age, BMI, pack years of smoking, number of cigarettes and FEV₁ % pred.

#Trend (0.05 < p. value < 0.1).

$Interaction between Phadiatop and treatment group has a p.value < 0.05.